نتایج جستجو برای: novoseven

تعداد نتایج: 115  

2005
Martin A Schreiber John B Holcomb Rasmus Rojkjaer

Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy of recombinant activated factor VII (rFVIIa; NovoSeven) in treating thrombocytopenic rabbits and for the reversal of anticoagulation. Safety models in the rabbit also exist to test for...

Journal: :Annales de biologie clinique 2006
F Barrier A de La Guerenne E Semjen L Wierre S Horrent B Decaudin J P Resibois M P Weillaert R Azar P Odou

We report the case of a 86-year-old man admitted in a local hospital with spontaneous haematoma, an isolated prolonged activated partial prothrombin time (114/32 seconds; ratio = 3.6), an anemia and a normal platelet count. Two diagnosis were suspected: a coagulation factor defect, or the presence of a lupus anticoagulant or of anti-factor antibodies. An acquired haemophilia A was confirmed wit...

Journal: :Anesthesiology 2003
Kenichi A Tanaka Amr A Waly William A Cooper Jerrold H Levy

CARDIAC surgery with cardiopulmonary bypass (CPB) poses serious hemostatic challenges in Jehovah’s Witnesses, who refuse blood transfusions on religious grounds. Excessive bleeding ( 2 l) after cardiac surgery is encountered in 5–7% of Jehovah’s Witness patients, and necessitates reexploration in 3.6% of cases. Recombinant factor VIIa (rFVIIa, NovoSeven®; Novo Nordisk, Princeton, NJ), produced ...

2009
Charlotte Bomken Sue Mathai Tina Biss Andrew Loughney John Hanley

Major obstetric haemorrhage remains a significant cause of maternal morbidity and mortality. Previous case reports suggest the potential benefit of recombinant activated factor VII (rFVIIa: NovoSeven(R)) as a haemostatic agent. We performed a retrospective review of the use of rVIIa in major obstetric haemorrhage in the Northern Region between July 2004 and February 2007. Fifteen women received...

2005
Aryeh Shander

ABSTRACT Objective: To rationalize decision-making concerning the growing and costly off-label use of recombinant human factor VII (rFVIIa, NovoSeven®) therapy. Options: Using rFVIIa therapy for patients with bleeding or providing usual care (e.g., continued clotting factor replacement). Outcome: Morbidity and mortality related to continued bleeding or thrombosis. Evidence: A literature review ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید